Synonym(s)
meta-tetrahydroxyphenylchlorine; mTHPC
DefinitionThis section has been translated automatically.
Temoporfin is a photosensitizing porphyrin derivative with a strong absorption maximum in the infrared spectrum at 652 nm.
Pharmacodynamics (Effect)This section has been translated automatically.
Formation of singlet oxygen in the irradiated cells, which leads to cell death. Shielding of the neighbouring tissue is absolutely necessary.
You might also be interested in
IndicationThis section has been translated automatically.
Approved for palliative treatment of patients with advanced squamous cell carcinoma of the head or neck in failure of previous therapies and inaccessibility to radiotherapy, surgical excision or systemic chemotherapy.
Pregnancy/nursing periodThis section has been translated automatically.
Insufficient data on use in pregnancy. Should not be prescribed during pregnancy.
Dosage and method of useThis section has been translated automatically.
Intravenous injection of 0,15 mg/kg bw Temoporfin. 96 hours after injection, irradiation by laser light of the wavelength 652 nm with a dose of 20 J/cm2. At a radiation power of 100 mW/cm2 this results in an irradiation time of approx. 200 seconds.
Undesirable effectsThis section has been translated automatically.
Local pain; allergic reactions to porphyrins.
ContraindicationThis section has been translated automatically.
- Porphyria
- Light Dermatoses
- tumor erosion into large blood vessels.
- Parallel treatment with photochemotherapy.
- Ophthalmological diseases requiring slit-lamp examinations within 30 days after application of Temoporfin.
- Allergic reactions to Temoporfin or other components of the preparation.
PreparationsThis section has been translated automatically.
Foscan ampoules of 3.5 and 5 ml (1 ml corresponds to 4 mg Temoporfin).
Note(s)This section has been translated automatically.
Strong photosensitization. Protection of eyes and skin absolutely necessary until 2 weeks (!) after treatment, then gradual adaptation to light.
LiteratureThis section has been translated automatically.
- Baas P (2001) Photodynamic therapy with meta-tetrahydroxyphenylchlorine for basal cell carcinoma: a phase I/II study. Br J Dermatol 145: 75-78
- Cramers P et al (2003) Foscan uptake and tissue distribution in relation to photodynamic efficacy. Br J Cancer 88: 283-290
- Javaid B et al (2002) Photodynamic therapy (PDT) for oesophageal dysplasia and early carcinoma with mTHPC (m-tetrahydroxyphenyl chlorin): a preliminary study. Lasers Med Sci 17: 51-56
- Jones HJ et al (2003) Photodynamic therapy effect of m-THPC (Foscan((R))) in vivo: correlation with pharmacokinetics. Br J Cancer 89: 398-404
- Kubler AC et al (2001) Treatment of squamous cell carcinoma of the lip using Foscan-mediated photodynamic therapy. Int J Oral Maxillofac Surgery 30: 504-509
- Morris K Ray (2000) of light for treatment of head and neck cancer. Lancet Oncol 1: 10
- Schmidt C et al (2003) Foscan - a new possibility for photodynamic therapy. Act Dermatol 29: 155-156
Prof. Dr. med. Peter Altmeyer